
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is expected to have a successful year in 2026, with the potential of achieving peak commercial revenue in the near future. Its proprietary ABC platform, highlighted by the potential of its investigational drugs tarcocimab tedromer, KSI-501, and KSI-101, holds great promise for retinal medicine by addressing the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. This, combined with its consistently positive clinical trial results, has led to a positive outlook on the company's stock and a strong belief in its potential for continued growth.
Bears say
Kodiak Sciences is seeing potential success with their Phase 3 GLOW program and anticipates FDA submission for tarcocimab based on its favorable safety and tolerability profile. With the upcoming Phase 3 DAYBREAK trial expected to confirm both the immediate and durable benefits of tarcocimab in wet AMD, Kodiak's unique ABC platform may establish differentiation within the retinal therapeutic landscape. However, concerns remain about the current unmet need of injection burden for traditional anti-VEGF treatments and will be closely monitored as Phase 3 GLOW2 data in diabetic retinopathy is expected in 1Q26.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares